We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK and CureVac in New Alliance for Multi-Valent mRNA COVID-19 Vaccines
GSK and CureVac in New Alliance for Multi-Valent mRNA COVID-19 Vaccines
GlaxoSmithKline (GSK) and Germany-based CureVac announced that they will co-develop a messenger-RNA-based COVID-19 vaccine to protect against multiple emerging variants of the SARS-CoV-2 virus.